Trade Coherus BioSciences - CHRS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023568% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001346% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.8 |
| Open | 0.77 |
| 1-Year Change | -67.23% |
| Day's Range | 0.73 - 0.79 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 3, 2025 | 0.80 | -0.01 | -1.23% | 0.81 | 0.82 | 0.79 |
| Apr 2, 2025 | 0.89 | 0.12 | 15.58% | 0.77 | 0.89 | 0.76 |
| Apr 1, 2025 | 0.78 | -0.01 | -1.27% | 0.79 | 0.83 | 0.77 |
| Mar 31, 2025 | 0.78 | -0.02 | -2.50% | 0.80 | 0.81 | 0.77 |
| Mar 28, 2025 | 0.82 | -0.01 | -1.20% | 0.83 | 0.86 | 0.81 |
| Mar 27, 2025 | 0.82 | -0.07 | -7.87% | 0.89 | 0.89 | 0.81 |
| Mar 26, 2025 | 0.88 | -0.05 | -5.38% | 0.93 | 0.94 | 0.87 |
| Mar 25, 2025 | 0.94 | 0.02 | 2.17% | 0.92 | 0.99 | 0.89 |
| Mar 24, 2025 | 0.93 | -0.08 | -7.92% | 1.01 | 1.04 | 0.93 |
| Mar 21, 2025 | 1.00 | 0.09 | 9.89% | 0.91 | 1.00 | 0.87 |
| Mar 20, 2025 | 0.92 | 0.02 | 2.22% | 0.90 | 0.94 | 0.88 |
| Mar 19, 2025 | 0.89 | 0.02 | 2.30% | 0.87 | 0.93 | 0.87 |
| Mar 18, 2025 | 0.87 | -0.04 | -4.40% | 0.91 | 0.91 | 0.85 |
| Mar 17, 2025 | 0.89 | -0.03 | -3.26% | 0.92 | 0.92 | 0.89 |
| Mar 14, 2025 | 0.90 | 0.03 | 3.45% | 0.87 | 0.97 | 0.87 |
| Mar 13, 2025 | 0.87 | -0.10 | -10.31% | 0.97 | 0.97 | 0.85 |
| Mar 12, 2025 | 0.96 | -0.05 | -4.95% | 1.01 | 1.03 | 0.96 |
| Mar 11, 2025 | 1.01 | 0.01 | 1.00% | 1.00 | 1.10 | 0.93 |
| Mar 10, 2025 | 1.02 | -0.01 | -0.97% | 1.03 | 1.14 | 1.01 |
| Mar 7, 2025 | 1.01 | 0.03 | 3.06% | 0.98 | 1.03 | 0.94 |
Why choose Capital.com? Our numbers speak for themselves.
Capital.com Group710K+
Traders
110K+
Active clients monthly
$214B+
Monthly trading volume
$55M+
Withdrawn each month
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Coherus BioSciences Company profile
About Coherus Biosciences Inc
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. It operates in the business of developing and commercializing the human pharmaceutical products segment. The Company’s product pipeline comprises three product candidates, toripalimab, an anti-PD-1 antibody being developed in collaboration with Junshi Biosciences Co., Ltd., CIMERLI, a Lucentis biosimilar candidate in-licensed for commercial rights in the United States and Canada from Bioeq, and a bevacizumab (Avastin) biosimilar in-licensed for commercial rights in the United States from Innovent Biologics (Suzhou) Co., Ltd. It is also developing an internal immuno-oncology pipeline in preclinical and translational science, bioinformatics, analytical characterization, process science engineering, and clinical-regulatory development and commercialization.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Coherus Biosciences Inc revenues decreased 31% to $326.6M. Net loss totaled $287.1M vs. income of $132.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects Research and development increase from $128.9M to $344.4M (expense), General and administrative increase of 20% to $138.1M (expense).
| Industry: | Bio Therapeutic Drugs |
C/O Dennis M. Lanfear
201 Redwood Shores Parkway, Suite 200
REDWOOD CITY
CALIFORNIA 94065
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com